Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19.
COVID-19
immunogenicity
preclinical trials
safety
toxicity
vaccine
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
30 11 2022
30 11 2022
Historique:
pubmed:
13
8
2022
medline:
2
11
2022
entrez:
12
8
2022
Statut:
ppublish
Résumé
This article describes the results of a preclinical safety and immunogenicity study of QazCovid-in®, the first COVID-19 vaccine developed in Kazakhstan, on BALB/c mice, rats, ferrets, Syrian hamsters and rhesus macaques (
Identifiants
pubmed: 35960911
doi: 10.1080/21645515.2022.2087412
pmc: PMC9621059
doi:
Substances chimiques
COVID-19 Vaccines
0
Viral Vaccines
0
Antibodies, Viral
0
Vaccines, Inactivated
0
Antibodies, Neutralizing
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2087412Références
Lancet Infect Dis. 2021 Aug;21(8):1107-1119
pubmed: 33773111
Nature. 2021 Feb;590(7845):320-325
pubmed: 33260195
Trials. 2020 Oct 15;21(1):853
pubmed: 33059771
Rev Med Virol. 2021 May;31(3):e2183
pubmed: 33594794
Nat Commun. 2021 Mar 1;12(1):1346
pubmed: 33649323
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Sci Rep. 2020 Sep 16;10(1):15188
pubmed: 32938954
Vaccine. 2017 Oct 13;35(43):5762-5767
pubmed: 28916246
Int J Antimicrob Agents. 2020 May;55(5):105951
pubmed: 32234466
Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6
pubmed: 15096611
Trials. 2021 Apr 13;22(1):276
pubmed: 33849629
DNA Cell Biol. 2004 Jun;23(6):391-4
pubmed: 15231072
Front Microbiol. 2021 Sep 27;12:720437
pubmed: 34646246
Vaccines (Basel). 2021 Mar 03;9(3):
pubmed: 33802467
Arch Virol. 2019 Apr;164(4):1027-1036
pubmed: 30740636
Clin Drug Investig. 2021 Jun;41(6):499-509
pubmed: 33754328
Drugs. 2021 Mar;81(4):495-501
pubmed: 33683637
Vaccine. 2018 Mar 27;36(14):1853-1862
pubmed: 29496347
iScience. 2021 Feb 19;24(2):102054
pubmed: 33521604
J Genet Genomics. 2021 Feb 20;48(2):107-114
pubmed: 34006471
NPJ Vaccines. 2022 Feb 23;7(1):24
pubmed: 35197485
Virol Sin. 2012 Dec;27(6):345-52
pubmed: 23180289
Vaccine. 2011 Apr 27;29(19):3596-9
pubmed: 21385634
J Pharmacol Toxicol Methods. 2012 Jul;66(1):1-7
pubmed: 22561062
Science. 2020 Jul 3;369(6499):77-81
pubmed: 32376603
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
J Microbiol Biotechnol. 2020 Mar 28;30(3):313-324
pubmed: 32238757
Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):
pubmed: 34193524
Int J Biol Sci. 2021 Apr 10;17(6):1446-1460
pubmed: 33907508
Viral Immunol. 2010 Oct;23(5):509-19
pubmed: 20883165
EClinicalMedicine. 2021 Sep;39:101078
pubmed: 34414368
J Virol. 2004 Jul;78(13):6938-45
pubmed: 15194770
J Virol. 2004 May;78(9):4638-45
pubmed: 15078946
Vaccines (Basel). 2021 Nov 17;9(11):
pubmed: 34835278
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
NPJ Vaccines. 2017 Oct 16;2:28
pubmed: 29263883
J Virol. 2013 Aug;87(16):9379-83
pubmed: 23785207
Cell. 2020 Aug 6;182(3):713-721.e9
pubmed: 32778225
BMC Complement Altern Med. 2016 Jul 27;16:249
pubmed: 27460904
Animal Model Exp Med. 2018 Nov 21;1(4):250-254
pubmed: 30891574
Sci Transl Med. 2015 Aug 19;7(301):301ra132
pubmed: 26290414
ERJ Open Res. 2020 Dec 07;6(4):
pubmed: 33313306
Pharmaceutics. 2019 Nov 23;11(12):
pubmed: 31771151